Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
PLX
Valuation N/A
Protalix BioTherapeutics, Inc.
Price$2.64
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +8.3% · above model
PLYX
Valuation N/A
Polaryx Therapeutics, Inc.
Price$2.01
Model IV—
P/IV—
Limited data — see page
PMCB
Valuation N/A
PharmaCyte Biotech, Inc.
Price$0.45
Model IV—
P/IV—
Limited data — see page
PMN
Valuation N/A
ProMIS Neurosciences Inc.
Price$13.56
Model IV—
P/IV—
Limited data — see page
PMVP
Valuation N/A
PMV Pharmaceuticals, Inc.
Price$1.40
Model IV—
P/IV—
Limited data — see page
PPBT
Valuation N/A
PURPLE BIOTECH LTD.
Price$1.72
Model IV—
P/IV—
Limited data — see page
PPCB
Valuation N/A
Propanc Biopharma, Inc.
Price$0.92
Model IV—
P/IV—
Limited data — see page
PRAX
Valuation N/A
Praxis Precision Medicines, Inc.
Price$330.55
Model IV—
P/IV—
Market implies +87.0%/yr
vs model +15.0% · above model
PRFX
Valuation N/A
PRF Technologies Ltd.
Price$0.86
Model IV—
P/IV—
Market implies +59.8%/yr
vs model +15.0% · above model
PRLD
Valuation N/A
Prelude Therapeutics Inc
Price$4.59
Model IV—
P/IV—
Market implies +64.0%/yr
vs model +15.0% · above model
PRME
Valuation N/A
Prime Medicine, Inc.
Price$3.13
Model IV—
P/IV—
Market implies +88.0%/yr
vs model +15.0% · above model
PROK
Valuation N/A
PROKIDNEY CORP.
Price$1.80
Model IV—
P/IV—
Limited data — see page
PRQR
Valuation N/A
ProQR Therapeutics N.V.
Price$1.86
Model IV—
P/IV—
Limited data — see page
PRTA
Valuation N/A
PROTHENA CORP PUBLIC LTD CO
Price$8.93
Model IV—
P/IV—
Market implies +72.8%/yr
vs model +2.0% · above model
PSNL
Valuation N/A
Personalis, Inc.
Price$16.21
Model IV—
P/IV—
Market implies +95.8%/yr
vs model +2.0% · above model
PTCT
Deeply undervalued
PTC THERAPEUTICS, INC.
Price$66.06
Model IV$345.26
P/IV0.21
Discount 81%
Return to IV: +422.6%
Market implies -4.3%/yr
vs model +25.0% · below model
PTGX
Valuation N/A
Protagonist Therapeutics, Inc
Price$148.18
Model IV—
P/IV—
Market implies +35.8%/yr
vs model +13.9% · above model
PTHS
Deeply overvalued
Pelthos Therapeutics Inc.
Price$21.90
Model IV$17.93
P/IV1.48
Premium +22%
Return to IV: -18.1%
Market implies -4.3%/yr
vs model +15.0% · below model
PTN
Valuation N/A
PALATIN TECHNOLOGIES INC
Price$10.94
Model IV—
P/IV—
Market implies -6.8%/yr
vs model +15.0% · below model
PVLA
Valuation N/A
PALVELLA THERAPEUTICS, INC.
Price$150.13
Model IV—
P/IV—
Market implies +53.5%/yr
vs model +15.0% · above model
PYXS
Valuation N/A
Pyxis Oncology, Inc.
Price$3.21
Model IV—
P/IV—
Market implies +38.4%/yr
vs model +15.0% · above model
QCLS
Valuation N/A
Q/C TECHNOLOGIES, INC.
Price$1.71
Model IV—
P/IV—
Limited data — see page
QGEN
Fairly valued
QIAGEN N.V.
Price$41.88
Model IV$49.10
P/IV0.75
Discount 15%
Return to IV: +17.2%
Market implies +1.9%/yr
vs model +4.5% · in line
QNCX
Valuation N/A
Quince Therapeutics, Inc.
Price$29.55
Model IV—
P/IV—
Limited data — see page
QSIAW
Valuation N/A
Quantum-Si Inc
Price$0.20
Model IV—
P/IV—
Market implies +28.1%/yr
vs model +15.0% · above model
QTRX
Deeply overvalued
Quanterix Corp
Price$2.50
Model IV$1.33
P/IV2.31
Premium +89%
Return to IV: -47.0%
Market implies +8.9%/yr
vs model +5.9% · above model
QTTB
Overvalued
Q32 Bio Inc.
Price$11.10
Model IV$9.47
P/IV1.17
Premium +17%
Return to IV: -14.7%
Market implies -6.3%/yr
vs model +12.2% · below model
QUCY
Valuation N/A
Quantum Cyber N.V.
Price$1.34
Model IV—
P/IV—
Market implies +60.5%/yr
vs model +15.0% · above model
QURE
Valuation N/A
uniQure N.V.
Price$43.10
Model IV—
P/IV—
Market implies +65.5%/yr
vs model +2.0% · above model
RADX
Valuation N/A
Radiopharm Theranostics Ltd
Price$1.98
Model IV—
P/IV—
Limited data — see page
RANI
Valuation N/A
Rani Therapeutics Holdings, Inc.
Price$0.84
Model IV—
P/IV—
Limited data — see page
RCUS
Valuation N/A
Arcus Biosciences, Inc.
Price$24.59
Model IV—
P/IV—
Market implies +101.2%/yr
vs model +2.0% · above model
RDY
Valuation N/A
DR REDDYS LABORATORIES LTD
Price$11.90
Model IV—
P/IV—
Limited data — see page
REPL
Valuation N/A
Replimune Group, Inc.
Price$12.92
Model IV—
P/IV—
Limited data — see page
REVB
Valuation N/A
REVELATION BIOSCIENCES, INC.
Price$0.96
Model IV—
P/IV—
Limited data — see page
RFL
Valuation N/A
Rafael Holdings, Inc.
Price$2.28
Model IV—
P/IV—
Market implies +118.2%/yr
vs model +2.0% · above model
RGEN
Valuation N/A
REPLIGEN CORP
Price$165.18
Model IV—
P/IV—
Limited data — see page
RGNX
Valuation N/A
REGENXBIO Inc.
Price$8.53
Model IV—
P/IV—
Market implies +57.1%/yr
vs model +2.0% · above model
RIGL
Deeply undervalued
RIGEL PHARMACEUTICALS INC
Price$47.24
Model IV$117.12
P/IV0.26
Discount 60%
Return to IV: +147.9%
Market implies +2.0%/yr
vs model +20.0% · below model
RKDA
Valuation N/A
Arcadia Biosciences, Inc.
Price$0.43
Model IV—
P/IV—
Market implies +20.3%/yr
vs model +0.0% · above model
RLAY
Valuation N/A
Relay Therapeutics, Inc.
Price$18.87
Model IV—
P/IV—
Market implies +64.5%/yr
vs model +50.0% · above model
RLYB
Valuation N/A
Rallybio Corp
Price$16.88
Model IV—
P/IV—
Market implies +56.9%/yr
vs model +15.0% · above model
RNA
Valuation N/A
Atrium Therapeutics, Inc.
Price$10.36
Model IV—
P/IV—
Limited data — see page
RNAC
Valuation N/A
Cartesian Therapeutics, Inc.
Price$8.19
Model IV—
P/IV—
Market implies +104.6%/yr
vs model +2.0% · above model
RNAZ
Valuation N/A
Transcode Therapeutics, Inc.
Price$1.60
Model IV—
P/IV—
Limited data — see page
RNTX
Valuation N/A
Rein Therapeutics, Inc.
Price$0.79
Model IV—
P/IV—
Limited data — see page
RNXT
Valuation N/A
RenovoRx, Inc.
Price$1.76
Model IV—
P/IV—
Market implies +48.2%/yr
vs model +15.0% · above model
ROIV
Valuation N/A
Roivant Sciences Ltd.
Price$40.82
Model IV—
P/IV—
Market implies +144.2%/yr
vs model +2.0% · above model
RPID
Valuation N/A
RAPID MICRO BIOSYSTEMS, INC.
Price$1.23
Model IV—
P/IV—
Market implies +21.1%/yr
vs model +9.7% · above model
RPRX
Deeply undervalued
Royalty Pharma plc
Price$58.61
Model IV$108.10
P/IV0.52
Discount 46%
Return to IV: +84.4%
Market implies -4.4%/yr
vs model +3.7% · below model
RSSS
Fairly valued
Research Solutions, Inc.
Price$2.14
Model IV$2.42
P/IV0.90
Discount 12%
Return to IV: +13.2%
Market implies +6.4%/yr
vs model +13.1% · below model
RVMD
Valuation N/A
Revolution Medicines, Inc.
Price$203.77
Model IV—
P/IV—
Market implies +126.5%/yr
vs model +15.0% · above model
RVMDW
Valuation N/A
Revolution Medicines, Inc.
Price$11.29
Model IV—
P/IV—
Market implies +91.9%/yr
vs model +2.0% · above model
RXRX
Valuation N/A
RECURSION PHARMACEUTICALS, INC.
Price$3.20
Model IV—
P/IV—
Market implies +35.4%/yr
vs model +50.0% · below model
RYTM
Deeply overvalued
RHYTHM PHARMACEUTICALS, INC.
Price$104.71
Model IV$20.71
P/IV4.26
Premium +406%
Return to IV: -80.2%
Market implies +21.8%/yr
vs model +50.0% · below model
RZLT
Valuation N/A
Rezolute, Inc.
Price$4.22
Model IV—
P/IV—
Limited data — see page
SABS
Valuation N/A
SAB Biotherapeutics, Inc.
Price$3.41
Model IV—
P/IV—
Market implies +60.4%/yr
vs model +15.0% · above model
SABSW
Valuation N/A
SAB Biotherapeutics, Inc.
Price$0.02
Model IV—
P/IV—
Limited data — see page
SANA
Valuation N/A
Sana Biotechnology, Inc.
Price$3.13
Model IV—
P/IV—
Limited data — see page
SCLX
Valuation N/A
Scilex Holding Co
Price$5.01
Model IV—
P/IV—
Limited data — see page